MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs).The downstream transcription factors that control responses like stress signaling, pathogen response, and hormone signaling are phosphorylated as a result of the activated MAPK.
The final protein in the cascade, a MAPK (ERK, p38, or JNK), is activated by the MAPKKK by phosphorylating a serine or threonine residue on a MAPKK. Mitogen-activated protein kinase kinase 3 (MKK3), MKK6, and occasionally MKK4 are primarily responsible for activating the p38 MAPK. Two upstream MAP2Ks, MKK4 and MKK7, control the JNK. Raf and Ras are activated by the highly homologous kinases MEK1 and MEK2, which then activate ERK mitogen-activated protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74094 | (R)-PD 0325901CL | 1003216-77-0 | (R)-PD 0325901CL is an isomer of PD 0325901CL. |
|
V3182 | APS-2-79 | 2002381-25-9 | APS-2-79 (APS-279) is a potent antagonist of MAPK (mitogen-activated protein kinase) with antitumor activity. |
|
V2664 | APS-2-79 HCl | 2002381-31-7 | APS-2-79 HCl (APS279 HCl; APS-279), the hydrochloride salt of APS-2-79, is an antagonist of MAPK (mitogen-activated protein kinase) with anticancer effects. |
|
V0458 | AZD8330 (ARRY704; ARRY424704) | 869357-68-6 | AZD8330 (AZD-8330; ARRY-704; ARRY-424704) is an orally bioactive and non-ATP competitive (Allosteric) MEK 1/2 inhibitor with potential anticancer activity. |
|
V0457 | BIX 02188 | 334949-59-6 | BIX02188 (BIX-02188), an indolinone analog, is a novel, highly potent and selective MEK5 inhibitor with the potential to relieve neuropathic pain. |
|
V0450 | BIX 02189 | 1094614-85-3 | BIX02189 is a novel, potent andselective inhibitor of MEK5 with important biological activity. |
|
V33372 | BIX02189 | 1265916-41-3 | BIX02189 is a novel, potent and selective MEK5 inhibitor with an IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with an IC50 of 59 nM. |
|
V97312 | DS03090629 | DS03090629 is an orally available MEK inhibitor that inhibits MEK activity in an ATP-competitive manner. | |
|
V0451 | GDC-0623 (G-868) | 1168091-68-6 | GDC-0623 (G868) is a novel, potent, orally bioactive, selective and non-ATP-competitive (allosteric) inhibitor of MEK1 with potential anticancer activity. |
|
V74088 | GSK1790627 | 871701-87-0 | GSK1790627 is the N-deacetylated metabolite of trametinib. |
|
V4731 | GW284543 | 790186-68-4 | GW284543 (also known as GW-284543; UNC10225170; UNC-10225170) is a novel, potent and selectiveMEK5inhibitor with potential usefulness in cancer treatment. |
|
V93759 | Luvometinib | 2739690-43-6 | Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity. |
|
V74092 | MEK-IN-6 | 2845151-86-0 | MEK-IN-6 (Example 69) is a MEK inhibitor. |
|
V74090 | MEK-IN-6 hydrate | 2845153-35-5 | MEK-IN-6 hydrate (compound 69) is a MEK inhibitor. |
|
V97290 | MEK/RAF-IN-1 | MEK/RAF-IN-1 (compound 16b) is a MEK and RAF inhibitor with IC50 values of 28, 3, and 3 nM for MEK1, BRAF, and BRAFV600E, respectively. | |
|
V83686 | MEK1/C-Raf-IN-1 | 946128-76-3 | |
|
V74091 | MEK4 inhibitor-1 | 2570386-36-4 | MEK4 inhibitor-1 is a new MEK4 inhibitor against pancreatic cancer, with IC50 of 61 nM. |
|
V74093 | MEK4 inhibitor-2 | 2833643-78-8 | MEK4 inhibitor-2 is a new MEK4 inhibitor against pancreatic cancer, with IC50 of 83 nM. |
|
V74087 | MS934 | 2756323-15-4 | MS934 is a novel improved VHL-recruiting MEK 1/2 degrader. |
|
V74089 | Nedometinib | 2252314-46-6 | Nedometinib is a tyrosine kinase inhibitor targeting MEK1. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
